Form 4: Intellia CMO Granted Equity Awards

Intellia Therapeutics' Chief Medical Officer, David Lebwohl, received grants of restricted stock units and stock options effective March 1, 2026.

Summary

• David Lebwohl, Executive Vice President and Chief Medical Officer of Intellia Therapeutics, Inc. (NTLA), was granted equity awards.
• Acquired 9,943 shares of Common Stock through Restricted Stock Units (RSUs) on March 1, 2026, at a price of $0.
• Acquired 14,204 stock options on March 1, 2026, with an exercise price of $13.78 per share.
• The RSUs represent a contingent right to receive one share of Intellia common stock for each unit.
• The stock options vest 33% on January 1, 2027, with the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
• Following these transactions, Lebwohl beneficially owns 131,192 shares of Common Stock and 14,204 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued executive commitment and standard compensation practices, which generally supports stability and aligns management incentives with shareholder interests.

Positives

• The grant of equity awards aligns the Chief Medical Officer's interests with those of shareholders, incentivizing long-term performance.
• Standard compensation practice for key executives, indicating stability in management structure.

Future Outlook

The vesting schedule for the granted stock options, with initial vesting on January 1, 2027, and subsequent monthly installments, indicates a long-term incentive structure for the Chief Medical Officer.

Industry Context

StockSavvy.ai notes that equity grants to executives are a standard practice in the biotechnology industry, aligning management incentives with shareholder value creation, particularly for companies like Intellia Therapeutics focused on long-term drug development and clinical milestones.

Comparison to Industry Standards

• StockSavvy.ai observes that equity compensation packages, including RSUs and stock options with multi-year vesting schedules, are common across the biotech sector, comparable to practices at companies such as CRISPR Therapeutics or Editas Medicine, aiming to retain key talent and incentivize performance over time.

Stakeholder Impact

• Shareholders: Benefit from aligned management incentives, potentially leading to better long-term company performance.
• Employees: Standard compensation practices can contribute to employee retention and morale, especially for key executives.

Next Steps

• Vesting of 33% of stock options on January 1, 2027.
• Remaining 67% of stock options to vest in 24 substantially equal monthly installments thereafter.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a standard compensation practice and does not provide new information to warrant a change in investment recommendation. It indicates continued alignment of management interests with shareholders but no fundamental shift in company prospects.

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, David Lebwohl, Chief Medical Officer, Biotechnology